Stock Updates

Is this Large Market Cap Stock target price reasonable for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

The company in question is, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) currently with a stock price of 52.88 (-2.42% today). The market cap for Sarepta Therapeutics, Inc. is 3056.86, and is in the sector Healthcare, and Biotechnology industry. The target price for Sarepta Therapeutics, Inc. is 73.43. Currently Sarepta Therapeutics, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Sarepta Therapeutics, Inc. is 4078.9 and so far today it is 1106901.

Performance in the last year for Sarepta Therapeutics, Inc. has been 86.48%. For EPS growth, Sarepta Therapeutics, Inc. has seen a growth of -53.40%, and is looking to grow in the next year to 68.80%. More long term stats show that EPS growth has been *TBA over the last five years and could be -0.20% for the next five years. Sarepta Therapeutics, Inc. has seen sales growth quarter over quarter at *TBA, with EPS growth quarter over quarter at -33.40%. The 20-day simple moving average is 36.62%, with the 200-day simple moving average coming to 121.10%.

Since the IPO date for Sarepta Therapeutics, Inc. on the 06/04/1997, Sarepta Therapeutics, Inc. has seen performance year to date to be 40.46%. With Sarepta Therapeutics, Inc. trading at 52.88, the dividend yield is *TBA, and the EPS is -5.35.

So could Sarepta Therapeutics, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 2351.43 and the P/B is at 20.6. The P/cash is 24.81, with P/free cash flow at *TBA.

Sarepta Therapeutics, Inc. ability to deal with debt shows that the current ratio is 2.3, and the quick ratio is 2.3. This is with long term debt/equity at 0.08, and total debt/equity at 0.17.

In terms of margins, Sarepta Therapeutics, Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Sarepta Therapeutics, Inc. is *TBA. Return on assets come to -109.00% with return on investment coming to -103.00%.

Insider ownership for Sarepta Therapeutics, Inc., is at 0.40% and institutional ownership comes to 66.10%. Outstanding shares are at 56.41. While shares float is 49.27. The float short is currently 28.98%, and short ratio is 3.5.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment